Active substanceSofosbuvir + VelpathaswirSofosbuvir + Velpathaswir Similar drugsTo uncover Epclus pills inwards Description:Active metabolite sophosbuvier is an inhibitor RNA polymerases hepatitis C virus (HCV). The new substance velpatasvir - inhibitor of RNA polymerase NS5B. The combination of sophosbuvira and vlepatasvira provides effective treatment of hepatitis C, caused by the virus of 1-6 genotypes. ATX: & nbspJ.05.A.X.15 Sofosbuvir Pharmacodynamics:Combined drug for treatment chronic viral hepatitis C, approved The US Food and Drug Administration (FDA) for use since June 28, 2016. The drug is effective in the therapy of all six genotypes of the virus that causes hepatitis C. Epclus preparation is given one tablet a day for about three months in combination with ribavirin.According to the conclusion of the FDA, the cure comes in 95% of cases.The advantage of Epclus when used with or without ribavirin is its very high efficacy against all HCV genotypes, including patients with decompensated hepatic cirrhosis. Side effects:In clinical studies, patients who took Epclus' drug were more likely to experience fatigue, headache, and nausea. Form release / dosage:Film-coated tablets: 400 mg of sophosbuvira and 100 mg of Velpathaswire Terms of leave from pharmacies:On prescription Registration number:in the Russian Federation is not registered Manufacturer: & nbspGilead Sciences Ireland UC Ireland Illustrated instructions × Illustrated instructions Instructions